Iodine-131 therapy for distant metastases of differentiat-ed thyroid carcinoma
LIN Yan-song
LI Ruo-chen
Abstract：Differentiated thyroid carcinoma(DTC)is a common type of thyroid cancer,including papillary thyroid carcinoma(PTC),follicular thyroid carcinoma(FTC),and oncocytic thyroid carcinoma(OTC).Although most patients with DTC have a favorable prognosis following surgery,radioactive iodine therapy(RAIT),and TSH suppression therapy,a subset of patients develop distant metastatic differentiated thyroid carcinoma(DM-DTC),with the lungs and bones being the most common sites of metastasis.RAIT is the first-line postoperative treatment for DM-DTC and can effectively reduce recurrence and mortality risks.The RAIT treatment plan for DM-DTC should be individualized based on the iodine uptake characteristics of the lesions.Research indicates that RAIT has a high complete remission rate for lung micro-metastases,while for bone metastases,although the cure rate is low,it significantly improves prognosis.Additionally,preparatory work before RAIT,such as elevated TSH levels and a low-iodine diet,significantly impacts treatment outcomes.The pre-assessment of iodine uptake capability(e.g.,Dx-WBS)and the detection of molecular characteristics(e.g.,BRAFV600E and TERT promoter mutations)help predict RAIT efficacy and the risk of RAIR-DTC.For patients who do not uptake iodine or have poor treatment responses,other local treatments or novel molecular-targeted drugs should be considered to improve survival rates and quality of life.Overall,RAIT plays a crucial role in of treating DM-DTC,but comprehensive decision-making and dynamic adjustments based on individual conditions are necessary.
Keywords：differentiated thyroid carcinomadistant metastat-icradioactive iodine-131 therapy
Publication Date：2024-06-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 619-624 )